GCG and Alzheimer disease: In previous pilot studies with GLP-1-RAs, 4 weeks of liraglutide intervention prevented the decline of glucose metabolism ([18F]FDG (FDG) in subjects with AD, although the study was unpowered to draw conclusions on the Aβ load or on cognition measures, which were unchanged [23].